We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Clinical Investigation To Evaluate Cerviron Ovules® in Symptomatic Vaginitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04735705
Recruitment Status : Completed
First Posted : February 3, 2021
Last Update Posted : September 10, 2021
MDX Research
Information provided by (Responsible Party):
Perfect Care Distribution

Brief Summary:

CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in patients with symptomatic, non-specific, non-infectious vaginitis, and endogenous symptomatic infections.

The secondary objective of this clinical investigation is the assessment of performance of the medical device by several additionally clinical outcomes (vaginal discharge, vaginal pH, microscopic characteristics of inflammatory cells and characteristics of vaginal microflora).

Participants will also evaluate the degree of satisfaction related to the use of the medical device.

Condition or disease Intervention/treatment Phase
Vaginitis and Vulvovaginitis Device: Cerviron Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis
Actual Study Start Date : April 1, 2021
Actual Primary Completion Date : September 9, 2021
Actual Study Completion Date : September 9, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaginitis

Arm Intervention/treatment
Experimental: Cerviron vaginal ovules
Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation.
Device: Cerviron
Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.

Primary Outcome Measures :
  1. Clinical Performance Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit [ Time Frame: 3 months ]
    Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation and/or pruritus and/or odor). Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.

  2. Rate of treatment-related Adverse Events in subjects participating in the clinical investigation [ Time Frame: 3 months ]
    The safety of CERVIRON ® as measured by the rate of treatmentrelated adverse events, including serious adverse events (SAEs), in subjects participating in the clinical investigation.

Secondary Outcome Measures :
  1. Change in Vaginal Discharge Aspect during Clinical Exam, Assessed by the Investigator [ Time Frame: at 1, 2 and 3 months ]

    The vaginal discharge assessed by the investigator by using a score:


    1. mild: insufficient for speculum collection
    2. moderate: sufficient for speculum collection
    3. abundant: visible at the introitus even before speculum introduction
    4. purulent, abnormal discharge: visible at the introitus even before speculum introduction

  2. Change in vaginal pH values [ Time Frame: at 1, 2 and 3 months ]
    Determination of pH values compared to its normal values (3.8 - 4.5)

  3. Change in vaginal microflora and Lactobacilli count [ Time Frame: 3 months ]
    The change in Lactobacillus species as shown by microscopy

  4. Change in vaginal inflammation [ Time Frame: 3 months ]
    The change in inflammatory and parabasal cells by microscopy

  5. Patient Satisfaction (Likert Scale) [ Time Frame: 3 months ]
    The degree of satisfaction when using the medical device will be assessed using a five-point Likert Scale.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult females, aged 18 years to 65 years;
  • Subjects presenting two or more vaginal symptoms such as leucorrhoea, pruritus, burning sensation, erythema, pain, odour, dysuria, or dyspareunia;
  • Subjects with a diagnosis of either non-infectious vaginitis, or endogenous, symptomatic infection;
  • Negative for Gardnerella vaginalis, Candida albicans, Trichomonas vaginalis;
  • Subjects willing to provide signed informed consent to clinical investigation participation.

Exclusion Criteria:

  • Subjects in menstrual period or suffering from menorrhagia;
  • Colpectomy;
  • Subjects with undiagnosed abnormal genital bleeding;
  • Subject with vulvar, vaginal or cervical cancer;
  • Known, active sexually transmitted infection (STI) in partner, as per anamnesis;
  • Subjects with HIV or other immunodeficiency;
  • Subjects with any pathology of the female reproductive organs;
  • Known allergy or hypersensitivity to the medical device ingredients;
  • Use of spermicides;
  • Use of diaphragm;
  • Concomitant topical or systemic anti-infective treatment;
  • Unable to comply with visit procedures;
  • Subjects included in other clinical investigations;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04735705

Layout table for location information
Spitalul Clinic Județean de Urgență "Pius Brinzeu"
Timisoara, Timiș, Romania
Institutul National pentru Sanatatea Mamei si Copilului (INSMC) "Alessandrescu - Rusescu"
Bucharest, Romania
Sponsors and Collaborators
Perfect Care Distribution
MDX Research
Layout table for investigator information
Study Director: Ramona Petrita, CSO MDX Research
Layout table for additonal information
Responsible Party: Perfect Care Distribution
ClinicalTrials.gov Identifier: NCT04735705    
Other Study ID Numbers: CYRON/01/2021
First Posted: February 3, 2021    Key Record Dates
Last Update Posted: September 10, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Perfect Care Distribution:
vaginal discharge, vaginal pH, vaginal microflora
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaginal Diseases
Vulvar Diseases